Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel method for preparing drotaverine hydrochloride intermediate

A technology for drotaverine hydrochloride and intermediates, which is applied in the field of preparation of drotaverine hydrochloride intermediates, and can solve the problems of higher requirements for operators

Active Publication Date: 2020-05-19
JIANGSU LIANHUAN PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The existing method for preparing 3,4-diethoxyphenylacetonitrile uses the highly toxic substance sodium cyanide, which has high requirements for operators, and in order not to pollute the environment, the cyanide-containing wastewater produced by the reaction needs to be treated separately to achieve discharge standard

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel method for preparing drotaverine hydrochloride intermediate
  • Novel method for preparing drotaverine hydrochloride intermediate
  • Novel method for preparing drotaverine hydrochloride intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] A kind of preparation new method of drotaverine hydrochloride intermediate 3,4-diethoxyphenylacetic acid (I), reaction process is as follows:

[0054]

[0055] Specifically include the following steps:

[0056] 1) Synthesis of 2-(3,4-diethoxy)phenyl-glyoxylic acid ethyl ester (IV)

[0057] Add 500mL dichloromethane, 260mmol AlCl 3 , stir. Cool down to -10~-5°C, and add 205 mmol ethyl oxalyl chloride dropwise. After stirring for 15 minutes, a solution of 200 mmol of 1,2-diethoxybenzene (III) in dichloromethane (60 mL) was added dropwise. After the dropwise addition, the temperature was raised to room temperature, and the reaction was completed for 1 hour. The temperature was lowered to below 0°C, and 150 mL of cold water was slowly added dropwise to the reaction solution. Transfer to a separatory funnel and let stand to separate layers. After the water layer was separated, it was washed once with 150 mL of saturated sodium bicarbonate solution, then once with 15...

Embodiment 2

[0065] A kind of preparation new method of drotaverine hydrochloride intermediate 3,4-diethoxyphenylacetic acid (I), reaction process is as follows:

[0066]

[0067] Specifically include the following steps:

[0068] 1) Synthesis of 1-(3,4-diethoxyphenyl)ethanone (VI)

[0069] Add 240 mL of dichloromethane, 338 mmol of zinc chloride, and 242 mmol of acetyl chloride into the reaction flask and stir. After cooling to below 0°C, add 241 mmol of 1,2-diethoxybenzene (III) in 80 mL of dichloromethane dropwise, and react at room temperature for 1 hour after the dropwise addition. Cool to below 0°C, add 100 mL of water and stir for 15 minutes. Transfer to a separatory funnel to separate the layers. The dichloromethane layer was washed with 50 mL of 2N sodium hydroxide solution, then washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a light yellow oil, which solidified into an off-white solid after refrigeration to obtain 2...

Embodiment 3

[0074] A kind of preparation new method of drotaverine hydrochloride intermediate 3,4-diethoxyphenethylamine (II), reaction process is as follows:

[0075]

[0076] Specifically include the following steps:

[0077] 1) 3, the synthesis of 4-diethoxyphenylacetamide (VII)

[0078] Add 134 mmol of 3,4-diethoxyphenylacetic acid (I), 150 mL of dichloromethane, and 0.5 mL of DMF into the reaction flask, and stir. Below 10°C, 161 mmol of oxalyl chloride was added dropwise, and then heated to room temperature to react for 1 hour. Dichloromethane was removed by concentration under reduced pressure. The residue was dissolved in 200 mL of tetrahydrofuran and transferred to a reaction flask. 100 mL of 50% aqueous hydroxylamine solution was added dropwise at 40°C and reacted at 40-50°C for 1 hour. Concentrate under reduced pressure to remove tetrahydrofuran, and adjust the pH value to 7-8 with 2N hydrochloric acid. Extract with ethyl acetate 100mL. The organic layer was washed with ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel method for preparing a drotaverine hydrochloride intermediate, belonging to the technical field of medicine synthesis. The preparation method comprises the following steps: preparing an intermediate 3,4-diethoxyphenylacetic acid with 1,2-diethoxybenzene as a raw material, and preparing the intermediate 3,4-diethoxyphenylacetamide with 3,4-diethoxyphenylacetic acid as a raw material. According to the novel process for preparing the drotaverine hydrochloride intermediate, a method for directly preparing 3,4-diethoxyphenylacetic acid and 3,4-diethoxyphenylethylamine is adopted, and a process for preparing 3,4-diethoxyphenylacetonitrile is avoided, so a reaction step of using sodium cyanide is avoided.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical synthesis, and in particular relates to a new method for preparing an intermediate of drotaverine hydrochloride. Background technique [0002] Drotaverine hydrochloride, chemical name: 1-{(3,4-diethoxyphenyl)methylene}-6,7-diethoxy-1,2,3,4 -Tetrahydroisoquinoline hydrochloride, trade name RNO-SPA (RNO-SPA), is a kind of antispasmodic drug developed by the Chinoin pharmaceutical factory, a joint venture company of France Sanofi Company in Hungary. The drug is a derivative of papaverine, which has a stronger relaxing effect on smooth muscle than papaverine, and has a relaxing effect on the intestinal tract, gallbladder, blood vessel walls and uterus. It does not affect the autonomic nervous system and has no effect on the normal motility of the gastrointestinal tract, so there are no adverse reactions to anticholinergic antispasmodics. It has wide adaptability and has satisfactory curative ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C51/09C07C51/00C07C59/64C07C67/317C07C69/734C07C67/343C07C69/738C07C45/46C07C49/84C07C231/02C07C235/34C07C213/00C07C217/60C07D217/20
CPCC07C51/09C07C51/00C07C67/317C07C67/343C07C45/46C07C231/02C07C213/00C07D217/20C07C59/64C07C69/734C07C69/738C07C49/84C07C235/34C07C217/60
Inventor 黄坤褚青松李威俞波贾志祥涂斌
Owner JIANGSU LIANHUAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com